The University of Oxford is studying a nasal spray version of the Oxford- AstraZeneca COVID-19 vaccine among 30 young, healthy volunteers, and will assess …
The University of Oxford is studying a nasal spray version of the Oxford- AstraZeneca COVID-19 vaccine among 30 young, healthy volunteers, and will assess the induced immune response, safety and any side effects. The early-stage trial will enroll adults aged 18 to 40 from the Oxford area, and researchers will conduct four months of follow-up, according to a release posted Thursday. “Some immunologists believe that delivering the vaccine to the site of infection may achieve enhanced protection, especially against transmission, and mild disease,” Dr. Sandy Douglas, clinician-scientist and chief investigator of the study, said in the release. “We hope this small safety-focused study will lay the foundation for future larger studies that are needed to test whether giving the vaccine this way does protect against coronavirus infection.
